Quest Diagnostics (DGX) Q3 Earnings Strength Sharpens Valuation Focus

Quest Diagnostics walked into its Q3 2026 report with a reputation as a steady cash generator in diagnostics and a stock that had already delivered mid‑single digit gains over the past month. The fresh numbers told a louder story. Revenue reached about US$3.1b and adjusted earnings per share landed at US$3.00, enough to push the shares up 1.8% on the day.

The real hook for investors is not the price pop. It is the clear earnings strength and raised full year outlook that now have to justify a richer looking P/E against healthcare peers.

Like the earnings power at Quest Diagnostics but uneasy about paying up for a richer P/E multiple in healthcare? Compare this setup with 30 resilient stocks with low risk scores to see which stocks pair steady cash generation with more conservative valuation profiles.

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs. Q3 2025): US$3,097m vs. US$2,816m (up about 10%)
• Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025): US$312m vs. US$243m (higher by roughly 28%)
• Basic EPS (Q3 2026 vs. Q3 2025): US$2.84 vs. US$2.17 (increase of about 31%)
• Adjusted Operating Margin (Q3 2026 vs. Q3 2025): 16.7% vs. roughly 16.3% (around 40 bps improvement)

Earnings tell part of the story for Quest Diagnostics, but investors who care about what they are really paying for usually focus on the cash flowing through the business. If you look at Quest Diagnostics' cash flows alone, the stock could be a dramatic 30% undervalued.

Quest Diagnostics: Earnings Momentum Backs Defensive Story

Quest Diagnostics looks like a steady healthcare workhorse, in line with the defensive thesis. Revenue rising 10% in Q3, with Diagnostic Information Services growing just over 10% and requisitions up 14.5%, points to broad demand rather than a one off spike. Adjusted operating margin edging higher to 16.7% and adjusted EPS moving to US$3.00 indicate that the model is scaling. Combined with raised full year guidance and healthy cash generation, the picture is of a resilient, cash generative platform that is still finding growth in newer consumer and specialty channels.

Risks Still Present, But Currently Contained

Bearish worries around reimbursement pressure and cost inflation are visible, yet not overpowering the story for Quest Diagnostics at this time. Management is flagging PAMA cuts and wage and fuel pressure, and Project Nova is expected to weigh on EPS this year. At the same time, margins are holding up, cash from operations is strong, and the preliminary PAMA impact quantified so far is modest relative to total revenue. The recent cybersecurity incident also appears operationally contained. Risks are present, but current trends indicate they are being managed rather than driving the results.

Access the analyst estimates for Quest Diagnostics to see where the consensus models quietly diverge on Quest Diagnostics' next few years, and where the street is really bracing for the first major inflection point beyond this reporting season.

Hunt For Quiet Disconnects

Quest Diagnostics just reported earnings and cash flow details that invite closer valuation work. The real opportunity is finding stocks that could be undervalued before the market corrects them.

• Company 1 - 35% below our estimate - expands advisory revenue as senior bankers convert a strong mandate pipeline into capital and private transactions.
• Company 2 - 41% below our estimate - channels capital investment and acquisitions into capacity for AI data centers, networking hardware customers and defense-focused electronic systems.
• Company 3 - 34% below our estimate - converts manufacturing wins into long-cycle production across complex aerospace, defense, healthcare and industrial programs.

Three companies from the same screener. Open all 30 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com